Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.

Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM.

Br J Cancer. 2011 Jun 28;105(1):65-73. doi: 10.1038/bjc.2011.143. Epub 2011 Jun 7.

2.

The epigenetic promise for prostate cancer diagnosis.

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W.

Prostate. 2012 Aug 1;72(11):1248-61. doi: 10.1002/pros.22459. Epub 2011 Dec 7. Review.

PMID:
22161815
3.

Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.

Henrique R, Jerónimo C.

Eur Urol. 2004 Nov;46(5):660-9; discussion 669. Review.

PMID:
15474280
4.

Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.

Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, Mo C, Qiu S.

PLoS One. 2013 Sep 20;8(9):e75283. doi: 10.1371/journal.pone.0075283. eCollection 2013. Review.

5.

APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.

Chen Y, Li J, Yu X, Li S, Zhang X, Mo Z, Hu Y.

Eur J Hum Genet. 2013 Sep;21(9):929-35. doi: 10.1038/ejhg.2012.281. Epub 2013 Jan 9. Review.

6.

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.

Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG.

J Cell Biochem. 2004 Feb 15;91(3):540-52. Review.

PMID:
14755684
7.

The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.

He WS, Bishop KS.

Expert Rev Mol Diagn. 2016 Aug;16(8):839-52. doi: 10.1080/14737159.2016.1197121. Epub 2016 Jun 20. Review.

PMID:
27254598
8.

[GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer].

Bastian PJ, Nakayama M, De Marzo AM, Nelson WG.

Urologe A. 2004 May;43(5):573-9. Review. German.

PMID:
15029477
9.

DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Hoque MO.

Expert Rev Mol Diagn. 2009 Apr;9(3):243-57. doi: 10.1586/erm.09.10. Review.

10.

Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.

Meiers I, Shanks JH, Bostwick DG.

Pathology. 2007 Jun;39(3):299-304. Review.

PMID:
17558856
11.

The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis.

Gao T, He B, Pan Y, Li R, Xu Y, Chen L, Nie Z, Gu L, Wang S.

PLoS One. 2013 May 13;8(5):e62950. doi: 10.1371/journal.pone.0062950. Print 2013. Review.

12.
13.

Urinary biomarkers for prostate cancer: a review.

Hessels D, Schalken JA.

Asian J Androl. 2013 May;15(3):333-9. doi: 10.1038/aja.2013.6. Epub 2013 Mar 25. Review.

14.

Prognostic DNA methylation markers for prostate cancer.

Strand SH, Orntoft TF, Sorensen KD.

Int J Mol Sci. 2014 Sep 18;15(9):16544-76. doi: 10.3390/ijms150916544. Review.

15.

Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer.

Yokoi K, Yamashita K, Watanabe M.

Int J Mol Sci. 2017 Mar 30;18(4). pii: E735. doi: 10.3390/ijms18040735. Review.

16.

Urinary EN-2 to predict prostate cancer: Systematic review and meta-analysis.

Rosa MID, Dondossola ER, Alexandre MCM, Madeira K, Cardoso FA, Grande AJ.

Rev Assoc Med Bras (1992). 2017 Jul;63(7):656-661. doi: 10.1590/1806-9282.63.07.656. Review.

17.

Methylated DNA and microRNA in body fluids as biomarkers for cancer detection.

Ma Y, Wang X, Jin H.

Int J Mol Sci. 2013 May 16;14(5):10307-31. doi: 10.3390/ijms140510307. Review.

18.

[Biomarkers of prostate cancer. A review].

Mearini E, Cottini E, Cochetti G, Antognelli C, Talesa V.

Minerva Urol Nefrol. 2010 Jun;62(2):163-78. Review. Italian.

PMID:
20562797
19.

Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement.

Heney D, Whicher JT.

Ann Clin Biochem. 1995 Jul;32 ( Pt 4):358-68. Review. No abstract available.

PMID:
7486794

Supplemental Content

Support Center